Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Harnessing New Players in Atherosclerosis to Treat Heart Disease

Tuesday, September 24, 2013 | 8:30 AM – 4:30 PM

The New York Academy of Sciences

Presented by the Biochemical Pharmacology Discussion Group

Atherosclerosis is defined as a chronic inflammatory disease affecting arterial blood vessels involving dysregulation of the endothelial-leukocyte adhesive interactions, increased leukocyte apoptosis within the plaque, and defective phagocytosis of apoptotic cells. Despite the key role of monocytes/macrophages in atherosclerosis, mounting evidence suggests that dysregulation of other cell types may be independent risk factors for atherosclerosis. Leukocytes are produced daily and are derived from hematopoietic stem and progenitor cells within the bone marrow in a process call hematopoiesis. A better understanding of this process will open an avenue to identify new targets to fight atherosclerosis.

*Reception to follow.

Organizers

Mercedes Beyna, MS

Pfizer Global Research and Development

Nadeem Sarwar, PhD

Pfizer Global Research and Development

Laurent Yvan-Charvet, PhD

INSERM U1065/UNS, C3M

Jennifer Henry, PhD

The New York Academy of Sciences

Speakers

Elena V. Galkina, MD, PhD

Eastern Virginia Medical School

Emmanuel L. Gautier, PhD

Washington University School of Medicine, St. Louis

Klaus Ley, MD

La Jolla Institute for Allergy and Immunology

Andrew H. Lichtman, MD, PhD

Brigham and Women’s Hospital, Harvard Medical School

Kathryn J. Moore, PhD

New York University Medical Center

Matthias Nahrendorf, MD, PhD

Harvard Medical School

Alan R. Tall, MD, PhD

Columbia University Medical Center

http://www.nyas.org/Events/Detail.aspx?cid=1103f191-2d94-4f37-b91f-64293dc88019